CHRS
Coherus Oncology, Inc.
CHRS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CHRS overall, supported by stronger fundamentals and lower modeled downside.
CHRS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CHRS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CHRS PE Valuation
CHRS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CHRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect CHRS's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CHRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.00 | -172% |
| Q2 2026 | -$1.06 | -166% |
| Q1 2026 | $1.64 | +$2.71 |
| Q4 2025 | $1.43 | +472% |
| Q3 2025 | $1.39 | +$1.43 |
| Q2 2025 | $1.61 | +$1.97 |
| Q1 2025 | -$1.07 | -$0.33 |
| Q4 2024 | $0.25 | +$2.78 |
CHRS has swung to a loss: it lost $1.00 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CHRS on earnings quality, reporting a profit while its opponent remains loss making.
CHRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.3M | +23% |
| Q2 2026 | $14.3M | +40% |
| Q1 2026 | $12.3M | +62% |
| Q4 2025 | $12.7M | -76% |
| Q3 2025 | $11.6M | -84% |
| Q2 2025 | $10.3M | -84% |
| Q1 2025 | $7.6M | -90% |
| Q4 2024 | $54.1M | -41% |
CHRS's revenue is recovering but still below its 2020 peak: $14M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -236% | +147 points |
| Q2 2026 | -226% | +218 points |
| Q1 2026 | -294% | +304 points |
| Q4 2025 | -360% | -282 points |
| Q3 2025 | -383% | -374 points |
| Q2 2025 | -444% | -412 points |
| Q1 2025 | -598% | -543 points |
| Q4 2024 | -78% | -2.7 points |
CHRS's operating margin was −236% last quarter, up 147 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CHRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CHRS on profitability, with a higher operating margin.
CHRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34M | +$12.3M |
| Q2 2026 | -$62.1M | -$15.5M |
| Q1 2026 | -$57.9M | -$32.1M |
| Q4 2025 | -$19.7M | -169% |
| Q3 2025 | -$46.3M | +$15.7M |
| Q2 2025 | -$46.6M | -178% |
| Q1 2025 | -$25.8M | +$20.9M |
| Q4 2024 | $28.6M | +$41.6M |
CHRS has burned cash in most quarters: −$174M over the past year, against −$90M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CHRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CHRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +154K shares |
| 1 year | +34% | +38.9M shares |
| 3 years | +78% | +67.7M shares |
| 5 years | +105% | +79.4M shares |
| Available history | +112% | +81.8M shares |
CHRS has 155M diluted shares, up 34% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CHRS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CHRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -2.9x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -0.7x | Net Cash |
| Q1 2020 | -0.7x | Net Cash |
| Q4 2019 | -0.9x | Net Cash |
CHRS has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CHRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 3.7 | Oversold |
CHRS's weekly RSI is 24 (oversold) and its Stochastic is 4 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CHRS PE vs Healthcare Sector
| Metric | CHRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CHRS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CHRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 43% below |
| 20 week MA | $1.21 | 55% below |
| 50 week MA | $1.46 | 63% below |
| 100 week MA | $1.30 | 58% below |
| 200 week MA | $2.34 | 77% below |
CHRS is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CHRS on trend strength, trading above more of its moving averages.
CHRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $17.4 | -4.7% |
| 2021 | $17.4 | $17.8 | +2.5% |
| 2022 | $17.8 | $6.45 | -64% |
| 2023 | $6.45 | $3.33 | -48% |
| 2024 | $3.33 | $1.49 | -55% |
| 2025 | $1.49 | $1.33 | -11% |
| 2026 YTD | $1.33 | $0.54 | -59% |
CHRS has finished four years in a row lower, and it's down 59% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CHRS on returns for 2026, with the stronger performance.